Cardiovascular Systems, Inc. (CSII): Price and Financial Metrics


Cardiovascular Systems, Inc. (CSII): $40.29

-0.54 (-1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CSII POWR Grades


  • CSII scores best on the Growth dimension, with a Growth rank ahead of 80.84% of US stocks.
  • The strongest trend for CSII is in Stability, which has been heading up over the past 31 weeks.
  • CSII ranks lowest in Sentiment; there it ranks in the 21st percentile.

CSII Stock Summary

  • The ratio of debt to operating expenses for Cardiovascular Systems Inc is higher than it is for about just 12.46% of US stocks.
  • CSII's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 15.34% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Cardiovascular Systems Inc is reporting a growth rate of 148.02%; that's higher than 87.94% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cardiovascular Systems Inc are EVER, INVE, FTHM, VCYT, and KIDS.
  • CSII's SEC filings can be seen here. And to visit Cardiovascular Systems Inc's official web site, go to www.csi360.com.

CSII Valuation Summary

  • CSII's EV/EBIT ratio is -71.8; this is 368.91% lower than that of the median Healthcare stock.
  • CSII's price/sales ratio has moved down 80.7 over the prior 183 months.
  • CSII's price/sales ratio has moved down 80.7 over the prior 183 months.

Below are key valuation metrics over time for CSII.

Stock Date P/S P/B P/E EV/EBIT
CSII 2021-01-13 7.7 6.7 -76.2 -80.9
CSII 2020-06-11 4.2 7.8 -105.0 -124.6
CSII 2017-03-17 4.6 7.9 -31.3 -28.5
CSII 2016-05-26 3.0 5.3 -9.0 -8.0
CSII 2015-04-17 7.6 8.2 -37.1 -34.3
CSII 2008-07-29 0.7 0.5 5.1 -2.1

CSII Growth Metrics

  • The 5 year revenue growth rate now stands at 42.47%.
  • The year over year net cashflow from operations growth rate now stands at -455.03%.
  • Its 4 year net income to common stockholders growth rate is now at 82.28%.
CSII's revenue has moved up $13,489,000 over the prior 34 months.

The table below shows CSII's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 230.532 -13.761 -23.302
2020-12-31 228.434 -11.452 -20.187
2020-09-30 232.599 -9.207 -23.532
2020-06-30 236.545 -12.765 -27.236
2020-03-31 262.233 3.876 -10.601
2019-12-31 264.369 4.902 -7.04

CSII Price Target

For more insight on analysts targets of CSII, see our CSII price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.44 Average Broker Recommendation 1.65 (Moderate Buy)

CSII Stock Price Chart Interactive Chart >

Price chart for CSII

CSII Price/Volume Stats

Current price $40.29 52-week high $48.28
Prev. close $40.83 52-week low $29.59
Day low $40.12 Volume 343,900
Day high $41.11 Avg. volume 216,911
50-day MA $40.24 Dividend yield N/A
200-day MA $39.87 Market Cap 1.62B

Cardiovascular Systems, Inc. (CSII) Company Bio


Cardiovascular Systems develops, manufactures, and markets devices for the treatment of vascular diseases, targeting a range of plaque types in leg arteries above and below the knee. The company was founded in 1989 and is based in St. Paul, Minnesota.


CSII Latest News Stream


Event/Time News Detail
Loading, please wait...

CSII Latest Social Stream


Loading social stream, please wait...

View Full CSII Social Stream

Latest CSII News From Around the Web

Below are the latest news stories about Cardiovascular Systems Inc that investors may wish to consider to help them evaluate CSII as an investment opportunity.

Were Hedge Funds Right About Cardiovascular Systems Inc (CSII)?

In this article we will check out the progression of hedge fund sentiment towards Cardiovascular Systems Inc (NASDAQ:CSII) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

Yahoo | July 30, 2021

Will Cardiovascular Systems (CSII) Report Negative Earnings Next Week? What You Should Know

Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 28, 2021

Cardiovascular Systems, Inc. to Attend Three Investor Conferences in August

ST. PAUL, Minn., July 27, 2021--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to attend three investor conferences in August.

Yahoo | July 27, 2021

FibroGen hurt by downgrades, Danaher given Street-high target - today's analyst action

Mario13/E+ via Getty Images FibroGen courts downgrades after FDA setback for Roxadustat  FibroGen (FGEN) has lost ~35.7% in the pre-market in reaction to its failure to win the endorsement from FDA’s expert panel for Roxadustat in anemia due to chronic kidney disease ((CKD)). The setback has triggered Several downgrades from Wall Street. Bank...

Seeking Alpha | July 16, 2021

Cardiovascular Systems stock drops after CMS proposes payment cuts, but Needham says buy on weakness

Shares of Cardiovascular Systems Inc. , a medical device company focused on treatments for vascular and coronary disease, tumbled 10.2% in afternoon trading, and has dropped 18.1% amid a four-day losing streak. Needham analyst Mike Matson noted that the Centers for Medicare & Medicaid Services'' (CMS) proposed physician fee schedule for 2022 includes cuts of about 22% to office-based lab (OBL) payments for peripheral atherectomy. He expects medical societies to oppose to the fee schedule changes. "We do not expect this to have much, if any, impact on [Cardiovascular Systems] even if the cuts happen," Matson said, because he believes the proposed codes leave plenty of profit for the OBL, OBLs account for only about one-fifth of the company''s overall sales and the company continued to se...

MarketWatch | July 15, 2021

Read More 'CSII' Stories Here

CSII Price Returns

1-mo -5.56%
3-mo 0.72%
6-mo -6.54%
1-year 32.19%
3-year 8.25%
5-year 107.89%
YTD -7.93%
2020 -9.94%
2019 70.55%
2018 20.26%
2017 -2.15%
2016 60.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.257 seconds.